213 related articles for article (PubMed ID: 35802462)
1. Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults.
Politikos I; Lau C; Devlin SM; Quach S; Lin A; Perales MA; Shah GL; Seo SK; Papanicolaou GA; Barker JN
Blood Adv; 2022 Dec; 6(24):6291-6300. PubMed ID: 35802462
[TBL] [Abstract][Full Text] [Related]
2. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant.
Lin A; Brown S; Chinapen S; Lee YJ; Seo SK; Ponce DM; Shahid Z; Giralt S; Papanicolaou GA; Perales MA; Shaffer BC
Blood Adv; 2023 Dec; 7(23):7153-7160. PubMed ID: 37906513
[TBL] [Abstract][Full Text] [Related]
3. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
[TBL] [Abstract][Full Text] [Related]
4. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
Hinman B; Cox J; Umoru G; Kamble R; Musick W
Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
[TBL] [Abstract][Full Text] [Related]
5. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
Hill JA; Zamora D; Xie H; Thur LA; Delaney C; Dahlberg A; Pergam SA; Leisenring WM; Boeckh M; Milano F
Blood Adv; 2021 Aug; 5(16):3113-3119. PubMed ID: 34402885
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of letermovir for cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplant recipients: A global systematic review.
Sepassi A; Saunders IM; Bounthavong M; Taplitz RA; Logan C; Watanabe JH
J Am Pharm Assoc (2003); 2023; 63(4):1138-1149. PubMed ID: 37207713
[TBL] [Abstract][Full Text] [Related]
7. The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients.
Sourisseau M; Faure E; Béhal H; Chauvet P; Srour M; Capes A; Coiteux V; Magro L; Alfandari S; Alidjinou EK; Simon N; Vuotto F; Karam M; Faure K; Yakoub-Agha I; Beauvais D
Blood Adv; 2023 Mar; 7(5):856-865. PubMed ID: 36350752
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
Saullo JL; Baker AW; Snyder LD; Reynolds JM; Zaffiri L; Eichenberger EM; Ferrari A; Steinbrink JM; Maziarz EK; Bacchus M; Berry H; Kakoullis SA; Wolfe CR
J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206
[TBL] [Abstract][Full Text] [Related]
9. Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: A single-center retrospective analysis.
Yoshimura H; Satake A; Ishii Y; Ichikawa J; Saito R; Konishi A; Hotta M; Nakanishi T; Fujita S; Ito T; Ishii K; Nomura S
J Infect Chemother; 2022 Sep; 28(9):1317-1323. PubMed ID: 35725529
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis.
Abidi MZ; Molina KC; Garth K; Gutman JA; Weinberg A
Transpl Infect Dis; 2023 Oct; 25(5):e14104. PubMed ID: 37436771
[TBL] [Abstract][Full Text] [Related]
11. Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis.
Toya T; Mizuno K; Sakurai M; Kato J; Mori T; Doki N; Masuda S; Aotsuka N; Tsukamoto S; Sakaida E; Nakajima Y; Fujisawa S; Machida S; Aoyama Y; Yokoyama H; Shono K; Hatta Y; Usuki K; Kataoka K; Kanda Y
Blood Adv; 2024 Mar; 8(5):1084-1093. PubMed ID: 38330190
[TBL] [Abstract][Full Text] [Related]
12. Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.
Koch K; Osswald L; Miller I; Braitsch K; Götze K; Bassermann F; Herhaus P; Verbeek M
Anticancer Res; 2022 Nov; 42(11):5431-5441. PubMed ID: 36288861
[TBL] [Abstract][Full Text] [Related]
13. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
[TBL] [Abstract][Full Text] [Related]
14. Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease.
Bansal R; Gordillo CA; Abramova R; Assal A; Mapara MY; Pereira MR; Reshef R
Transpl Infect Dis; 2021 Apr; 23(2):e13487. PubMed ID: 33034124
[TBL] [Abstract][Full Text] [Related]
15. Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients.
Golob S; Batra J; DeFilippis EM; Uriel M; Carey M; Gaine M; Mabasa A; Fried J; Raikelkar J; Restaino S; Hi Lee S; Latif F; Yuzefpolskaya M; Colombo PC; Choe J; Majure D; Jennings D; Pereira MR; Clerkin K; Sayer G; Uriel N
Clin Transplant; 2022 Dec; 36(12):e14808. PubMed ID: 36086937
[TBL] [Abstract][Full Text] [Related]
16. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
17. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K
Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275
[TBL] [Abstract][Full Text] [Related]
18. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation.
Sharma P; Gakhar N; MacDonald J; Abidi MZ; Benamu E; Bajrovic V; Purev E; Haverkos BM; Tobin J; Kaiser J; Chase S; Miller M; Weinberg A; Gutman JA
Bone Marrow Transplant; 2020 Apr; 55(4):780-786. PubMed ID: 31664185
[TBL] [Abstract][Full Text] [Related]
19. Letermovir as Cytomegalovirus Prophylaxis in a Pediatric Cohort: A Retrospective Analysis.
Kuhn A; Puttkammer J; Madigan T; Dinnes L; Khan S; Ferdjallah A; Kohorst M
Transplant Cell Ther; 2023 Jan; 29(1):62.e1-62.e4. PubMed ID: 36244677
[TBL] [Abstract][Full Text] [Related]
20. CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre-emptive monitoring in the era of letermovir.
Yong MK; Slavin MA; Chemaly RF; Papanicolaou GA
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14171. PubMed ID: 37864299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
